Ampreloxetine Funding (Details) $ in Millions		12 Months Ended
	Jul. 20, 2022 USD ($)	Dec. 31, 2023	Dec. 31, 2022 USD ($)
Ampreloxetine Royalty Rights
Development and Collaboration Agreement
Consideration Receivable at closing	$ 25.0
Consideration received at the time of first approval	$ 15.0
Patent application period	5 years
Milestone payments	$ 15.0
Carrying amount of the liability			$ 25.0
Percent of effective interest rate		8.80%
Ampreloxetine Royalty Rights | Net Sales Upto First 500 Million
Development and Collaboration Agreement
Consideration received	$ 500.0
Royalty Payment Percentage Multiplied with Net Sales	2.5
Ampreloxetine Royalty Rights | Net Sales In Excess of 500 Million
Development and Collaboration Agreement
Consideration received	$ 500.0
Royalty Payment Percentage Multiplied with Net Sales	4.5
Ampreloxetine Funding
Development and Collaboration Agreement
Consideration Receivable at closing	$ 25.0